S-14671
S-14671 is a drug that was developed by the pharmaceutical company Servier. It is classified as an antidepressant, specifically a serotonin-norepinephrine reuptake inhibitor (SNRI).
Pharmacology[edit | edit source]
S-14671 works by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters in the brain. This increases the amount of these neurotransmitters available in the brain, which can help to alleviate symptoms of depression.
Development and Clinical Trials[edit | edit source]
S-14671 was developed by Servier Laboratories, a French pharmaceutical company. It underwent clinical trials to assess its safety and efficacy as a treatment for depression. However, the results of these trials have not been publicly disclosed, and it is unclear whether the drug is currently being marketed.
Side Effects[edit | edit source]
As with all drugs, S-14671 has the potential to cause side effects. These can vary widely between individuals and may include nausea, headache, insomnia, and dizziness. It is important for patients to discuss any potential side effects with their healthcare provider before starting treatment.
See Also[edit | edit source]
S-14671 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD